Effect of miR-145 on MCF-7 breast cancer cells by regulating disintegrin-metalloproteinase-17 / 医学研究生学报

Objective MicroRNA-145 (miR-145) is underexpressed in breast cancer. The study aimed to explore the regulatory effect of miR-145 on breast cancer MCF-7 cells by investigating the association of miR-145 with ADAM17 and EGFR. Methods The MCF-7 breast cancer cells were divided into three groups: the transfection group (transfected with microRNA-145 mimics), the control group (without transfection) and the nonsense sequence group (transfected with nonsense microRNA). MTT, transwell and real-time quantitative fluorescence polymerase chain reaction(qPCR) were respectively used to detect the proliferative capacity, invasive ability and expression of MCF-7 breast cancer cells after the transfection of miR-145 in three groups. ADAM17 and EGFR mRNA and protein levels in three groups of breast cancer MCF-7 cells were detected by qPCR and western blot. Results The results of qPCR showed that the relative expression of miR-145 was significantly higher in transfection group (13964.33±1265.30) than those in control group (1.00±0.05) and nonsense sequence group (1.03±0.15) and the difference was statistically significant (P<0.01); the expression of ADAM17 mRNA in transfection group (1.71±0.08) was significantly higher than that in control group (1.00±0.07) and the difference was statistically significant (P<0.01). Compared with the nonsense sequences at 24 h, 48 h, and 72 h, the inhibition rate of MCF-7 in transfection group was significantly increased (P<0.01). The results of transwell invasion showed that the number of transmembrane cells in transfection group [(56.20±2.17)/field] was significantly lower than those in control group [(92.80±3.90)/field] and nonsense sequence group [(91.80±4.97)/field of view ] (P < 0.01). Western blot results showed that the protein content of ADAM17 and EGFR in transfection group was significantly lower than those in the control group and the nonsense sequence group (P<0.01). Conclusion MiR-145 inhibits the proliferation and invasion of breast cancer MCF-7 cell line by acting on the ADAM17-EGFR signaling pathway.

Activation and enhancement of room-temperature ferromagnetism in Cu-doped anatase TiO2 films by bound magnetic polaron and oxygen defects.

Cu-doped anatase TiO2 films grown by magnetron sputtering at room temperature showed the unexpected observation of room-temperature ferromagnetism, which was enhanced or destroyed corresponding to low or high impurity concentration via vacuum annealing. On the basis of the analysis of composition and structure, the most important factor for activating ferromagnetism can be identified as the creation of grain boundary defects. In addition, oxygen defects can be the dominating factor for increasing the saturation moment of the 0.19 at. % Cu-doped TiO2 film from 0.564 to 26.41 emu/cm(3). These results help elucidate the origin of ferromagnetism and emphasize the role of oxygen defects for the application of ferromagnetic films.

Anatase TiO2 films with dominant {001} facets fabricated by direct-current reactive magnetron sputtering at room temperature: oxygen defects and enhanced visible-light photocatalytic behaviors.

A TiO2 film with dominant anatase {001} facets is directly prepared by direct-current reactive magnetron sputtering at room temperature without using morphology-controlling agents. The formation mechanism of anatase TiO2 films with dominant {001} facets is explained by the competition between thermodynamics and ion impinging in the deposition process. The crystalline TiO2 film shows a superior photocatalytic efficiency for the degradation of Rhodamine B under UV-visible (λ > 250 nm) lights. Furthermore, a comparable photodegradation of Rhodamine B is also found on the TiO2 film surface by using visible (λ > 420 nm) lights. During film growth, the surface bombarded by high energy of ions yields plenty of oxygen defects, which can enhance the photocatalytic activity of the films irradiated under visible light.

Natural hydrophobicity and reversible wettability conversion of flat anatase TiO2 thin film.

Flat anatase TiO2 thin film deposited at room temperature shows the natural hydrophobicity, which is destroyed by 400 °C vacuum annealing. On the basis of the analysis of surface composition and structure, the origin of hydrophobicity of the flat TiO2 film can be identified as (1) approximately fully stoichiometric TiO2 and (2) hydrocarbon adsorbates on the film surface. We further validate that interfacial water molecules near the surface of the as-prepared TiO2 film are oriented in the hydrophobic hydration structure via Fourier transform infrared/attenuated total reflection. Moreover, the as-prepared TiO2 film also shows a smart surface reversibly switched between hydrophobicity and super-hydrophilicity. During the recovery process of hydrophobicity, the irradiated films show the wettability with water contact angle of 107 ± 1.7, 72 ± 2.5, 80 ± 1.1, and 17 ± 1.3° corresponding to after a week of exposure to ambient air, O2, CF4, and Ar, respectively. It can be strongly reinforced that the stoichiometry and the adsorbates both play an important role in forming the hydrophobic TiO2 films.

Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas / 中华医学杂志(英文版)

<p><b>BACKGROUND</b>The prognosis of unresectable large hepatocellular carcinomas is poor. This study evaluated the efficacy and safety of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation in the treatment of hepatocellular carcinomas larger than 5 cm.</p><p><b>METHODS</b>The treatment of 22 patients with large, unresectable hepatocellular carcinomas (5.0-16.5 cm) treated with sorafenib after transcatheter arterial chemoembolization combined with radiofrequency ablation between 2007 and 2011 was reviewed. The local effects, survival rates, toxicity, and prognostic factors were analyzed.</p><p><b>RESULTS</b>During a follow-up of 9-49 months, 19 patients died and three survived. The median overall survival was 32 months. The overall cumulative 12, 24, and 36-month survival rates were 85.9%, 66.8%, and 23.5% respectively. Technical effectiveness was achieved in 12 out of 28 lesions (42.85%) at the first CT check. The median time to tumor progression was 21 months. The progression-free survival rates at 6, 12, and 24 months were 90.9%, 72.0%, and 38.4%, respectively. Combined therapy was generally well tolerated. There was only one major procedure-related complication, biloma (4.5%). Sorafenib-related adverse events exceeding grade 3 were hand-foot skin reaction (2/22, 9.1%), gastrointestinal hemorrhage (1/22, 4.5%), and diarrhea (2/22, 9.1%). The absence of vascular invasion before treatment was found to be the best prognostic factor in the univariate analysis.</p><p><b>CONCLUSIONS</b>Sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation is a promising approach to the treatment of large, unresectable hepatocellular carcinomas. However, large-scale randomized clinical trials are needed to determine the future role of this treatment.</p>

Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed.

The purpose of this study is to analyze the safety and clinical efficacy of transcatheter arterial chemoembolization (TACE) combined with portal vein stent and ¹²5I implantation for the treatment of portal vein tumor thrombus (PVTT) in hepatocellular carcinoma. Fifty-six patients from our department diagnosed with advanced hepatocellular carcinoma with PVTT between January 2008 and December 30, 2010 were divided into two groups. Patients in Group A were treated with TACE and portal vein stent; patients in Group B were treated with TACE, portal vein stent and ¹²5I implantation. The success rate of TACE with portal vein stent and ¹²5I implantation was 100%, with no severe surgery-related complications. After an 8 mo follow-up, the total clinical benefit rates were 56.7 and 88.5% for Groups A and B, respectively (p < 0.05). The median survival times (mOS) for the two groups were 5.7 and 8.9 mo, respectively (p < 0.05). The median time of progression (mTTP) of the two groups were 5.3 and 7.9 mo, respectively (p < 0.05). The 2, 6, 8, 12 and 18 mo patency rates in Group A were 100, 93.3, 83.3, 53.3 and 36.6%. Those in Group B were 100, 100, 92.3, 84.6 and 80.7%. The 2, 6 and 8 mo patency rates showed no statistical differences (p > 0.05), but the 12 and 18 mo rates did (p < 0.05). Our results suggest that TACE combined with portal vein stent and ¹²5I implantation are both safe and effective, and ¹²5I implantation can further postpone the restenosis of the portal vein effectively.

The diagnosis and therapy of intractable upper gastrointestinal hemorrhage caused by hepatic arterioportal vein fistulas in hepatocellular carcinoma / 中华放射学杂志

Objective To investigate the hemodynamics of increasing portal venous pressure(PVP) in hepatocellular carcinoma patients complicated with hepatic arterioportal vein fistulas (HAPVF)and the diagnosis and therapy of intractable upper gastrointestinal hemorrhage caused by HAPVF.Methods One hundred and fifteen cases of hepatocellular carcinoma with upper gastrointestinal hemorrhage were checked by hepatic arteriography and were treated through orifices embolization in cases with severe HAPCF by coils and/or ethanol. Results Twenty-six out of 31 patients suffering intractable upper gastrointestinal hemorrhage have severe HAPVF(the main stem of portal veins are visible).However,there are only 15 patients with light HAPVF among the 84 patients who have mild upper gastrointestinal hemorrhage (the main stem of portal veins are invisible).After the embolization,all of the 26 patients who have severe HAPVF stopped bleeding.Among them,the main stem of hepatic arteries are occluded in 2 patients. Conclusion The existence of severe HAPVF should be taken into consideration when intractable upper gastrointestinal hemorrhage occurs in hepatocellular carcinoma patients,and it can be diagnosed through hepatic artery DSA.Orifice embolization is the most effective method for such kind of hemorrhage.